# US 2021/0330673 A1 · Multi-kinase inhibitors of vegf and tgf beta and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330673 A1
- Document ID: US20210330673A1
- Status: Published application
- Kind: A1
- Application number: 17/267,938
- Filed: 2019-08-13
- Published: 2021-10-28
- Earliest claimed: 2018-08-15
- Assignees: Aiviva Biopharma, Inc.
- Applicants: Aiviva Biopharma, Inc.
- Inventors: Gerald Woodrow DeVries; Diane Tang-Liu
- Web page: https://patentgrep.com/patent/US20210330673A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.

## Claims

### Claim 1

A method of treating a disease or disorder characterized by chronic inflammation, angiogenesis, fibrosis, or a combination thereof, comprising administering axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib to a mammal in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mammal is a human being.

### Claim 3 (depends on 1)

The method of claim 1, wherein axitinib is administered to the mammal in need thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein nintedanib is administered to the mammal in need thereof.

### Claim at position 5

-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein sunitinib is administered to the mammal in need thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein lenvatinib is administered to the mammal in need thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein regorafenib is administered to the mammal in need thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein ponatinib is administered to the mammal in need thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein or pazopanib is administered to the mammal in need thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib is administered to the mammal to treat a dermal-related disorder.

### Claim 14 (depends on 1)

The method of claim 1, wherein axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib is administered to the mammal to treat a benign prostate hyperplasia related disorder.

### Claim 15 (depends on 1)

The method of claim 1, wherein axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib is administered to the mammal to treat an eye-related disorder.

### Claim 16 (depends on 1)

The method of claim 1, wherein axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib is administered to the mammal to treat a rosacea-related disorder.

### Claim 17

(canceled)

### Claim 18 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is psoriasis.

### Claim 19 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is erythema multiforme.

### Claim 20 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is squamous cell carcinoma.

### Claim 21 (depends on 15)

The method of claim 15, wherein the eye-related disorder is ocular fibrosis.

### Claim 22 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is a non-melanoma skin cancer.

### Claim 23 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is actinic keratosis.

### Claim 24 (depends on 13)

The method of claim 13, wherein the dermal-related disorder is basal cell carcinoma.
